Roxadustat

B+

Pharmacology

Roxadustat increases endogenous EPO and hemoglobin through HIF prolyl-hydroxylase inhibition.

Roxadustat enhances physical performance in animals, most notably endurance, and does this effectively. It also potentially improves POTS, but is untested.

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral therapeutic agents that promote accumulation of HIF transcription factors and expression of HIF-responsive genes, leading to increased synthesis of EPO and proteins involved in iron metabolism.

Estimated effective dose is 50-70mg Every 2-3 days.